Skip to main content

Table 2 General characteristics and changes for subjects with detectable HIV replication

From: Human immunodeficiency virus type I-specific CD8+T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy

ID Duration of infection aVL zenith bCD4 nadir cVL study course dCD4i CD4f eMonths study course fCD8+ IFNγ+ CD45RA+ i CD8+ IFNγ+ CD45RA+ f
11 >15 yrs >5.88 63 4.58 308 335 60 15% 16%
17 >15 yrs 4.48 296 4.12 518 490 30 ND ND
35 >15 yrs 4.77 176 3.37 660 736 48 35% 12%
39 >15 yrs 5.64 24 2.70 754 961 30 6% 14%
51 >15 yrs 5.61 40 3.29 390 297 36 33% 25%
57 >15 yrs 5.48 176 4.25 420 506 36 14% 8%
77 >15 yrs 5.00 207 3.80 692 288 24 ND ND
78 >15 yrs >5.88 32 4.53 110 184 36 24% 23%
85 >14 yrs 4.60 307 2.65 684 663 66 11% 11%
98 >13 yrs 5.73 69 3.79 484 435 48 ND ND
116 >12 yrs 5.56 44 3.22 319 378 48 23% 23%
125 >12 yrs 5.06 59 4.52 496 209 42 31% ND
187 >7 yrs 3.93 1064 2.89 1127 1419 36 37% ND
195 >5 yrs 4.93 462 4.54 518 462 24 27% 25%
209 >5 yrs 4.97 500 4.72 812 500 24 ND ND
  1. aThe highest recorded virus load (VL) for each subject in log10 copies HIV RNA/mL plasma.
  2. bThe lowest recorded peripheral blood CD4+ T lymphocyte count for each subject.
  3. cVirus load (log10 copies HIV RNA/mL plasma) averaged over the 4 time points for each subject.
  4. dThe number of CD4+ T lymphocytes/μL peripheral blood for each subject at beginning (CD4i) and end (CD4f) of period over which HIV-specific CD8+ T cell responses were assessed.
  5. eTotal time period over which four assessments of HIV-specific CD8+ T cell responses occurred.
  6. fPercentage of HIV-specific CD8+ T cells producing INF-γ that expressed CD45RA at beginning (i) and end (f) of period over which HIV-specific CD8+ T cell responses were assessed.